Navigation Links
New Phase 3 Study in Treatment-Naive Adults with HIV Evaluates Efficacy and Safety of Once-Daily PREZISTA(TM)/ritonavir vs. KALETRA(R) as Part of HIV Combination Therapy
Date:9/18/2007

ith HIV medications and had a viral load greater than 5,000 copies. Overall the study population had a mean baseline viral load of 4.85 log10 copies per mL and a median CD4+ cell count of 225 cells per cubic millimeter.

Patients were randomized to receive PREZISTA/r 800 mg/100 mg once daily (n=343) or, based on approved dosing in each country, either lopinavir/r 800 mg/200 mg once daily or 400 mg/100 mg twice daily (n=346), plus a background regimen of tenofovir and emtricitabine once daily. Patient randomization was stratified based on viral load and CD4+ cell count.

ARTEMIS: 48-week study results

In the per-protocol analysis of 689 patients, among patients randomized to the once-daily PREZISTA/r arm (n=343) vs. the lopinavir/r arm (n=346), the 48-week analysis showed that:

-- 84 percent of patients in the PREZISTA/r arm reached an undetectable

viral load (<50 copies/mL) vs. 78 percent of patients in the

lopinavir/r arm.

-- The median change in CD4+ cell count from baseline was similar between

the PREZISTA/r and lopinavir/r arms (137 cells per cubic millimeter vs.

141 cells per cubic millimeter).

ARTEMIS: Safety findings

-- In the two study arms the adverse events at least Grade 2 in severity

included diarrhea, nausea and rash. Diarrhea was 4.1 percent in the

PREZISTA/r arm vs. 9.8 percent in the lopinavir/r arm. Nausea was 1.7

percent in the PREZISTA/r arm vs. 2.9 percent in the lopinavir/r arm.

Rash was 2.6 percent in the PREZISTA/r arm vs. 1.2 percent in the

lopinavir/r arm.

-- Incidence of Grade 3-4 lipid-related adverse events reported in

PREZISTA/r arm were 1.7 percent vs. 5.2 percent in the lopinavir/r arm.

-- In both treatment arms there was a low incidence of discontinuation.

Discontinuations due to adverse events were 3.4 percent in the

PREZISTA/r arm vs. 6.9 percent in the lopinavir/r arm.


'/>"/>
SOURCE Tibotec Therapeutics
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7

Related medicine technology :

1. Data Available From Erbitux Phase III Study in First-Line Treatment of Advanced Lung Cancer
2. Phase 3 Results for Dabigatran Etexilate, an Investigational Oral Anticoagulant, Presented Today at the XXIst Congress of the International Society on Thrombosis and Haemostasis
3. YM BioSciences Announces Secondary Efficacy and Safety Findings in Randomized Phase IIB Aerolef Trial
4. Portola Pharmaceuticals Announces Positive Data from a Phase II Study of its Factor Xa Inhibitor at the XXI Congress of the International Society on Thrombosis and Haemostasis
5. Manhattan Pharmaceuticals Announces Results of Phase 2a Studies for Oral Oleoyl-estrone
6. Actemra (tocilizumab) Third Phase III Study Results Show Significant Improvement in Symptoms of Patients with Rheumatoid Arthritis
7. AVI BioPharma Partner Cook Medical Announces Completion of Patient Enrollment for APPRAISAL Phase II Clinical Trial for Treatment of Cardiovascular Disease
8. NexMed Announces Completion of Patient Enrollment in Two Pivotal Phase 3 Studies for Anti-Fungal Product
9. AM-Pharma Announces Positive Results of Phase IIa Clinical Trial with Alkaline Phosphatase For Ulcerative Colitis
10. Phase III Trial Results Show Superiority of Rivaroxaban over Enoxaparin for the Prevention of Venous Thromboembolism in Patients Undergoing Knee Replacement Surgery
11. Phase III Trial Results Show Superiority of Rivaroxaban over Enoxaparin for the Prevention of Venous Thromboembolism in Patients Undergoing Knee Replacement Surgery
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/21/2014)... --  Wellcentive , the industry leader in end-to-end ... today being named one of the four finalists ...  Sponsored by Intel, the world leader in computing ... companies developing leading-edge technology and unique approaches to ... Wellcentive,s Mason Beard , senior vice ...
(Date:11/21/2014)... , Nov. 21, 2014  Lexicon Pharmaceuticals, Inc. ... has priced its offering of $80,000,000 aggregate principal amount ... Notes") in a private offering within the ... to qualified institutional buyers pursuant to Rule 144A under ... Act"). Lexicon has also granted the initial purchasers an ...
(Date:11/18/2014)... , Nov. 18, 2014 Respiratory Motion and ... leading medical device and services providers in ... for Respiratory Motion,s innovative respiratory depression monitor, the ExSpiron™. ... IMI are working together to connect the clinical community ... long history of bringing innovative medical devices and new ...
Breaking Medicine Technology:Wellcentive Named Finalist for 2014 Intel Innovation Award 2Wellcentive Named Finalist for 2014 Intel Innovation Award 3Lexicon Announces Pricing Of Convertible Senior Notes Offering 2Lexicon Announces Pricing Of Convertible Senior Notes Offering 3Prominent Japanese Med Device Provider to be Respiratory Motion's Exclusive Partner for World's #2 Medical Market 2Prominent Japanese Med Device Provider to be Respiratory Motion's Exclusive Partner for World's #2 Medical Market 3Prominent Japanese Med Device Provider to be Respiratory Motion's Exclusive Partner for World's #2 Medical Market 4
... Nov. 12 Based on its recent analysis ... & Sullivan presents Fovia, Inc. with the 2009 ... Innovation of the Year. Fovia is being recognized ... platform that offers unrivaled image quality and uncompromised ...
... Corporation (Nasdaq: THOR ), a world leader in ... restore failing hearts, said today that it will webcast ... II Destination Therapy clinical trial that will be presented ... American Heart Association(AHA) Scientific Sessions 2009. , The event ...
Cached Medicine Technology:Frost & Sullivan Recognizes Fovia for its HDVR(R) Platform - A Disruptive Technology Breakthrough 2Frost & Sullivan Recognizes Fovia for its HDVR(R) Platform - A Disruptive Technology Breakthrough 3Frost & Sullivan Recognizes Fovia for its HDVR(R) Platform - A Disruptive Technology Breakthrough 4
(Date:11/23/2014)... 23, 2014 Today Zane Benefits, ... small businesses, announced their new on demand webinar ... Employer-Provided Health Insurance. , According to ... financial risk facing most American families. It is ... and large, when it comes to recruiting and ...
(Date:11/22/2014)... Recently, UWDress.com, a successful wedding dress shop, has ... in order to prepare for the wedding season. All ... off. , UWDress.com is a reliable company that has ... the new items -- formal wedding guest attire. This new ... including superstar and princess. As one of the leading companies ...
(Date:11/22/2014)... NY (PRWEB) November 22, 2014 ... Goods Administration (TGA) approved it for use “as ... approved and listed within the Therapeutic Goods (Listing) ... , Kyowa Hakko’s Setria® Glutathione will be ... biotech specialist that sources and imports fine chemicals ...
(Date:11/22/2014)... November 22, 2014 "My friend went ... caused by the machine," said an inventor from Cambria ... to go back a second time because the first ... , She developed the patent-pending MAMO EASY to offer ... The design saves the patient from the pain normally ...
(Date:11/22/2014)... York (PRWEB) November 22, 2014 Lipitor ... behalf of patients who allegedly developed Type 2 diabetes ... the federal multidistrict litigation now underway in U.S. District ... According to court documents, the litigation will convene its ... The Court has directed Lead Counsel for Plaintiffs and ...
Breaking Medicine News(10 mins):Health News:Zane Benefits, Inc. Announces New Webinar on The End of Employer-Provided Health Insurance Now Available On-Demand! 2Health News:Formal Wedding Guest Attire Added to UWDress.com 2Health News:Setria® Glutathione Now Available in Australia 2Health News:Setria® Glutathione Now Available in Australia 3Health News:Lipitor Lawsuit Conference Scheduled for December, Bernstein Liebhard LLP Reports 2Health News:Lipitor Lawsuit Conference Scheduled for December, Bernstein Liebhard LLP Reports 3
... finds people who participated in a cardiac-rehab program after a ... as those of the same age and sex who had ... of the deaths that occurred among patients in their study ... ,The investigation involved about 1,800 patients. Nearly 60 percent ...
... low-glycemic index diet can lead to weight loss, reduced ... and cardiovascular disease. In low-GI foods, carbohydrates are low ... include white bread, refined breakfast cereals and concentrated sugars, ... to high levels. Carbs that release sugar more slowly ...
... A new study shows consuming foods or supplements containing the ... way to avoid Alzheimer’s disease // even if you carry ... the study researchers first bred mice to carry the gene ... Initially various environmental factors affecting the symptoms were studied but ...
... at an increased risk of dying from heart disease. ... more traits of metabolic syndrome have a 3.5-times higher ... syndrome is a group of metabolic risk factors including ... disorders, insulin resistance or glucose intolerance, and high-normal blood ...
... Mental decline usually associated with age, might affect women ... according to a recent study .// ,The ... worse cognitive performance and are at an increased risk ... cognitive impairment among women with pre-diabetes or diabetes was ...
... the number of Americans living with high blood pressure has ... pressure is defined // as having blood pressure of 140/90 ... their doctors at least twice that their blood pressure is ... ,However researchers say the study did not examine the reasons ...
Cached Medicine News:
With the Symphony family of Pacemakers, Ela presents the most advanced technology on the market. Symphony, lighter than a passport, will take your patients further, offering fast follow-up, using new...
... Exclusive Measuring System delivers precise and accurate ... are receiving a better examination when they ... Hi-tech equipment. ,User Friendly - after only ... personnel can become very proficient in the ...
Gentle curve facilitates less traumatic removal from eye. Increased length ideal for myopic eyes...
Curved Cannula for probing and irrigating lacrimal duct. 0.80mm (21 G)...
Medicine Products: